Advertisement

Usefulness of serum amyloid a protein dosage for monitoring patients receiving tocilizumab

Published:January 13, 2020DOI:https://doi.org/10.1016/j.ejim.2019.12.011
      Tocilizumab (TCZ) is a humanized monoclonal antibody directed against the interleukin-6 (IL-6) receptor licensed for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis and giant cell arteritis or used off label in other refractory autoimmune diseases [
      • Michaud M.
      • Lidove O.
      • Bienvenu B.
      • Chiche L.
      • Urbanski G.
      TOCIMAI Investigators group
      Effectiveness and tolerance of off-label use of tocilizumab in autoimmune diseases: a multicenter study.
      ,
      • Samson M.
      • Espigol-Frigolec G.
      • Terrades-Garciac N.
      • Prieto-Gonzalezc S.
      • Corbera-Bellaltac M.
      • Alba-Rovirac R.
      • et al.
      Biological treatments in giant cell arteritis & takayasu arteritis.
      ,

      Samson M., Devilliers H., Ly K.H., Maurier F., Bienvenu B., Terrier B. et al. Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of giant cell arteritis: a prospective study.Eur J Intern Med2018;57:96–104.

      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Michaud M.
        • Lidove O.
        • Bienvenu B.
        • Chiche L.
        • Urbanski G.
        • TOCIMAI Investigators group
        Effectiveness and tolerance of off-label use of tocilizumab in autoimmune diseases: a multicenter study.
        Joint Bone Spine. 2019; https://doi.org/10.1016/j.jbspin.2019.08.002
        • Samson M.
        • Espigol-Frigolec G.
        • Terrades-Garciac N.
        • Prieto-Gonzalezc S.
        • Corbera-Bellaltac M.
        • Alba-Rovirac R.
        • et al.
        Biological treatments in giant cell arteritis & takayasu arteritis.
        Eur J Intern Med. 2018; 50: 12-19
      1. Samson M., Devilliers H., Ly K.H., Maurier F., Bienvenu B., Terrier B. et al. Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of giant cell arteritis: a prospective study.Eur J Intern Med2018;57:96–104.

        • Smolen J.S.
        • Schoels M.M.
        • Nishimoto N.
        • Breedveld F.C.
        • Burmester G.R.
        • Dougados M.
        • et al.
        Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.
        Ann Rheum Dis. 2013; 72: 482-492
        • Stone J.H.
        • Tuckwell K.
        • Dimonaco S.
        • Klearman M.
        • Aringer M.
        • Blockmans D.
        • et al.
        Glucocorticoid dosages and acute‐phase reactant levels at giant cell arteritis flare in a randomized trial of tocilizumab.
        Arthritis Rheum. 2019; 71: 1329-1338
        • Hachulla E.
        • Saile R.
        • Parra H.J.
        • Hatron P.Y.
        • Gosset D.
        • Fruchart J.C.
        • et al.
        Serum amyloid a concentrations in giant-cell arteritis and polymyalgia rheumatica: a useful test in the management of the disease.
        Clin Exp Rheumatol. 1991; 9: 157-163